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Abstract 
Psychogenic movement disorders (PMDs) represent a complex and severe form of 
psychopathology, which even after a century of research remains poorly understood.  As 
previous investigations have neglected to differentiate symptom phenotypes and have 
approached assessment from the perspective of cognitive dysfunction apparent in PMD 
patient’s “neurological” counterparts, the current study aimed to examine the 
neurocognitive performance and psychological profiles of PMD patients with 
hyperkinetic motor manifestations guided by a theoretical lens of frontal lobe pathology 
and informed by previous neuroimaging studies with this patient population.  Subsequent 
to diagnostic confirmation of their condition by means of video-electroencephalographic 
monitoring or adherence to Fahn and Williams criteria, 16 patients with psychogenic 
non-epileptic seizures (PNES) and 16 patients with other hyperkinetic PMDs were 
administered an abbreviated neuropsychological battery and completed a series of self-
report measures assessing psychological functioning.  Results of the present study 
suggest that patients with psychogenic conditions demonstrate specific neurocognitive 
deficits mediated by frontal lobe structures, and that severity of posttraumatic 
symptomatology may be predictive of general cognitive impairment in this patient 
population.  When considered in the context of extant neurobiological data, the present 
findings generally support a cortico-limbic disconnection conceptualization of 
psychogenic illness.  The diagnostic and conceptual implications of these findings are 
discussed, as well as treatment implications for motor subgroups based on psychological  
vi 
 
and neurocognitive discrepancies observed between patients with PNES and other 
hyperkinetic PMDs.  Future investigators are encouraged to adopt a multidisciplinary 
approach employing recent technological advances and utilizing theoretical models 
guided by empirically established principles of neurocognitive functioning. 
1 
Introduction 
Background  
The myriad of motor manifestations currently designated as psychogenic 
movement disorders (PMDs) has traditionally been assumed to represent maladaptive 
coping mechanisms, which enable traumatically induced psychological and psychosocial 
distress to be expressed (Alsaadi & Marquez, 2005; Freud, 1910).  This interpretation is 
also supported by research demonstrating affective dysregulation in individuals with 
PMD (Prigatano & Kirlin, 2009; Scaer, 2001).  Although many of these patients also 
suffer from comorbid affective and neurological conditions that could very well produce 
abnormal neural activity, some researchers have begun to identify potential 
neurobiological abnormalities specific to this form of conversion disorder (Friedman & 
LaFrance, 2010; Nowak & Fink, 2009; Rowe, 2010; Stone et al., 2007).  Nevertheless, 
PMDs continue to be considered medically unexplained symptoms and individuals with 
these conditions are often referred from the diagnosing physician to clinicians in the 
psychiatric community for treatment (Barry & Sanborn, 2001; Carton, Thompson, & 
Duncan, 2003; Strutt, Hill, Scott, Uber-Zak, & Fogel, 2011a).  
It is postulated that nearly 3% of all cases evaluated at movement disorder clinics 
suffer from PMD, and that psychogenic tremor (14-65%), dystonia (24-54%), and 
myoclonus (0-19%) constitute the greatest frequency of phenotypes encountered (Hallett 
et al., 2006; Thomas, Vuong, & Jankovic, 2006).  However, in addition to PMD 
manifested by these phenotypes and other abnormal movements, psychogenic patients  
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may also present with the absence of normal motor function (e.g. paralysis) and/or 
abnormal sensory phenomenon (Hallett et al., 2006; Rowe, 2010).  A variety of other 
motor manifestations are also frequently encountered in such settings, including 
psychogenic non-epileptic seizures (PNES), which are paroxysmal episodes resembling 
epilepsy—most commonly imitating epileptic complex partial episodes—but which occur 
in the absence of electroencephalographic abnormalities (Hallett et al., 2006).  Non-
epileptic activity is estimated to occur in 5-20% of outpatients and 10-40% of inpatients 
referred for epilepsy evaluations (Benbadis & Hauser, 2000; Reuber & Elger, 2003).   
Consistent with the traditional Freudian conceptualization of PMDs, the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR) classifies these sensorimotor abnormalities as conversion disorders 
(American Psychiatric Association, 2000).  Alternatively, extant experimental data 
linking dissociative pathology with PMDs has been sufficiently convincing that the 
International Classification of Diseases, Tenth Revision (ICD-10) now classifies this 
condition as a dissociative disorder (Brown, Cardena, Nijenhuis, Sar, & Van der Hart, 
2007; World Health Organization, 1992).  However, despite the lack of consensus 
regarding the nosology and psychiatric classification of PMDs, both classification 
systems agree that these are neurological symptoms without a known neurological cause 
that are not intentionally produced, and which are assumed to have psychological 
underpinnings (Reuber & Mayor, 2012).  While video-electroencephalographic (video-
EEG) monitoring remains the “gold standard” for differentiating epileptic seizures (ES) 
from PNES, such technology is not readily available outside of epilepsy centers and 
several factors have been noted to limit the utility (e.g., comorbid ES and PNES, failure 
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to experience an attack during monitoring, some ES patients with EEG activity within 
normal limits, etc.) and reliability (e.g., moderate inter-rater agreement) of this 
technology (Reuber & Mayor, 2012).  Additionally, despite the establishment of 
operationalized diagnostic criteria for other PMD subtypes (i.e., Fahn-Williams criteria: 
Fahn & Williams, 1988; Williams, Ford, & Fahn, 1995; Shill-Gerber criteria: Shill & 
Gerber, 2006; Gupta and Lang revisions: Gupta & Lang, 2009), the diagnosis of PMD 
remains a “crisis for neurology” (Hallett, 2006). 
Demographic Profile 
The age of onset for PMD can range from early childhood to late adulthood with a 
mean age of approximately forty-four years (Thomas & Jankovic, 2004).  PMDs are 
more common in females than males (Hallett et al., 2006), and some evidence suggests 
that it may also be more prevalent in certain U.S. ethnic minority groups (3-4%) than the 
general population (<0.03%; Benbadis & Hauser, 2000).  Traumatic experiences have 
been cited as a potential risk factor for PNES, as such patients tend to report considerable 
rates of trauma (44-100%) and abuse (23-77%; Arnold & Privitera, 1996; Bowman & 
Markand, 1996; Fizman, Alves-Leon, Nunes, D’Andrea, & Figueira, 2004; Fleisher et al., 
2002; Griffith, Polles, & Griffith, 1998; Synder, Rosenbaum, Rowan, & Strain, 1994).  A 
significantly higher prevalence of posttraumatic stress disorder (PTSD) has also been 
found in PNES samples than in the general population, along with the associated PTSD 
symptom of dissociation (Dikel, Fennel, & Gilmore, 2003; Marchetti et al., 2008; 
Rosenberg, Rosenberg, Williamson, & Wolford, 2000), leading some researchers to 
suggest that PNES may be a related condition (Fizman et al., 2004).  
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Although psychiatric comorbidity estimates vary considerably, depression, 
anxiety and dissociative disorders are concomitant conditions repeatedly associated with 
PMDs (Araujo Filho & Caboclo, 2007; Fleisher et al., 2002; Hallett et al., 2006; 
Marchetti et al., 2008).  However, a recent study conducted by Van Merode and 
colleagues (2004) suggests that co-morbid Axis I disorders actually afflict PMD patients 
prior to the onset of motor manifestations and that chronic anxiety may be a factor 
conferring risk to the initial development of this condition.    Moreover, the dissociative 
symptoms frequently observed in PMD patients have been shown to correlate 
significantly with both physical and sexual abuse (Chu, Frey, Ganzel & Matthews, 1999; 
Draijer & Langeland, 1999), as well as other forms of childhood trauma (e.g., emotional 
abuse and neglect) frequently reported by PMD patients (Kuterovac-Jagodic, 2003; 
Roelofs, Keijsers, Hoogduin, Naring, & Moene, 2002; West, Adam, Spreng, & Rose, 
2001).  Also, consistent with the proposed pattern of dissociation in PMD (i.e. 
dissociative amnesia), Chu’s et al. (1999) research demonstrated that a considerable 
proportion of participants reporting histories of abuse or trauma had either partial or 
complete amnesia for those events.  However, not all individuals suffering from PMD 
claim to have experienced abuse or trauma, and while such events may indeed serve an 
etiological role in the development of this affliction, the relationship appears to be more 
complex than originally assumed (Edwards & Bhatia, 2012; Stone & Edwards, 2011; 
Kranick, et al., 2011).  
Unfortunately, however, there remains a paucity of research investigating 
variables that may potentially modify the relationship between trauma histories and 
dissociative tendencies.  While this void may have contributed to the conflicting findings 
5 
regarding PMDs, such results could also be the product of inappropriate methodology, 
the most notable of which includes the heterogeneity of PMD samples utilized in 
research, along with a tendency for investigators to neglect phenotype distinctions 
(Rowe, 2010; Stone, Sharpe & Binzer, 2004).  The few studies that have compared the 
features of PMD patients with different motor manifestations have yielded significant 
results (Abubakr, Kablinger & Caldito, 2003; Crimlisk et al., 1998; Stone et al., 2004).  
For instance, research conducted by Stone and colleagues (2004) with a sample of 
consecutive neurological inpatients found that PNES cases tended to occur at a 
significantly younger age than other motor conversion symptoms and were more likely to 
be associated with external factors.  If, as Stone et al. (2004) suggest, the only feature 
uniting these disorders is their physical imitation of neurological conditions, then further 
research with more homogeneous PMD samples and motor phenotype distinctions is 
warranted.   
Psychological & Neuropsychological Features 
Given that the diagnosis of PMD remains one of exclusion, differential diagnosis 
can pose considerable difficulty (Hallett et al., 2006).  In a recent survey study of over 
five hundred members of the Movement Disorder Society conducted by Espay et al. 
(2009), seventy-one percent of neurologists indicated that they involved psychiatrists or 
other mental health professionals in the diagnosis of PMD.  As such, neuropsychologists 
are frequently called upon to provide additional data that may be utilized to confirm a 
psychogenic diagnosis, as well as to assess the functional status of PMD patients.  
Traditional assessment methods of PMD have included examination of semiological 
features and personality profiles by neurologists and neuropsychologists, respectively 
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(Bodde et al., 2011; Hallet et al., 2006).  Greater affective distress compared to “organic” 
neurological conditions has also traditionally been taken to suggest a psychogenic 
diagnosis (Hallett et al., 2006).  However, recent research indicates that depressive 
symptoms are severe and common in both patients with psychogenic and “organic” 
neurological conditions, and thus, not effective in differentiating these patient populations 
(Asmussen, Kirlin, Gale, & Chung, 2009; Hesdorffer, Hauser, Olafsson, Ludvigsson, & 
Kjartansson, 2006; Strutt, Hill, Scott, Uber-Zak, & Fogel, 2011b).   
Alternatively, some evidence suggests that more specific affective symptoms may 
differentiate PMD patients from their neurological counterparts.  For instance, Asmussen 
et al. (2009) also observed comparable depression severity in PNES and ES patients, yet 
closer examination of the data revealed significantly higher physiological symptoms of 
depression in psychogenic patients, especially females.  Such findings correspond with 
the elevated rates of somatization symptoms (Locke et al., 2010; Reuber et al., 2003) and 
impaired affective perception and expression observed in PMD samples (Prigatano & 
Kirlin, 2009).  Additionally, several studies have identified a greater severity of 
dissociative symptoms in PMD patients (Brown et al., 2007; Goldstein, Mellers, 
O’Malley, & Oakley, 2000; Reuber, House, Pukrop, Bauer, & Elger, 2003; Van Merode 
et al., 2004), as well as chronic anxiety (Strutt et al., 2011b; Van Merode et al., 2004), 
and general psychopathology (Reuber et al., 2003; Van Merode et al., 2004).  Other 
findings from psychological research with PNES samples suggest that, unlike their ES 
counterparts, these patients tend to appraise stressful life events as significantly more 
distressing (Testa et al., 2012), exhibit a greater external control orientation regarding 
health factors (Goldstein et al., 2000; Strutt et al., 2011b), and utilize passive coping 
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strategies (e.g., denial, dissociation/mental disengagement, and escape-avoidance) more 
frequently (Goldstein et al., 2000; Testa et al., 2012).  However, the relationship between 
such symptoms remains a controversy, and some evidence suggests that the 
psychological disturbances observed in PNES patients may differ in severity from those 
with other PMDs, as well as vary across semiology-based subtypes of PNES patients 
(Griffith et al., 2007; Kranick, Ekanayake, Martinez, Ameli, Hallett, & Voon, 2011).  
In contrast to the relatively consistent psychological findings in PMD patients, the 
vast majority of extant data concerning neurocognitive functioning in this patient 
population is devoid of consensus (Barry & Sanborn, 2001; Carton, Thompson, & 
Duncan, 2003; Dodrill, 2010), with some studies demonstrating PMD patient cognitive 
abilities within normal limits (Drane et al., 2006), and others suggesting general 
neuropsychological impairments in PMD patients equivalent to their neurological 
counterparts (Binder, Kindermann, Heaton, & Salinsky, 1998; Dodrill, 2008; Drake, 
1993; Fargo et al., 2004; Hermann, 1993; McNally et al., 2009; Van Beilen, Griffioen, & 
Leenders, 2009; Wilkus, Dodrill, & Thompsom, 1984).  Some researchers have also 
identified specific neurocognitive deficits in PMD patients, sometimes in the presence of 
otherwise intact cognition, including: impairments in fine motor skills (Criswell et al., 
2010; Kalogjera-Sackellares & Sackellares, 1999; Sackellares & Sackellares, 2001); 
bilateral weakness (Sackellares & Sackellares, 2001); poor attention and working 
memory (Black et al., 2010; Strutt et al., 2011a); executive dysfunction and impaired 
problem-solving (Black et al., 2010; Kalogjera-Sackellares & Sackellares, 1999); finger 
agnosia (Binder et al., 1994); impaired lexical versus semantic fluency (Strutt et al., 
8 
2011a); and below average verbal memory and confrontation naming abilities (Prigatano 
& Kirlin, 2009). 
Despite the lack of consensus regarding specific deficits and neurocognitive 
profiles in PMD patients, altogether the extant data is suggestive of some form of 
neuropsychological compromise within this patient population.   Nevertheless, proposed 
explanations for the variation observed across studies have included the higher incidence 
of neurological injury observed in PMD patients (Fiszman et al., 2004; Wilkus & Dodrill, 
1989; Wilkus et al., 1984), anxiety (Prigatano & Kirlin, 2009), negative response bias 
(McNally et al., 2009), pessimistic attributional style (Griffith et al., 2008), and even 
inadequate effort (Drane et al., 2006).  However, while the results of Drane et al.’s (2006) 
study would seem to challenge the validity of previous neuropsychological findings, a 
multitude of subsequent studies have been unable to replicate their results, demonstrating 
instead that PMD patients put forth valid effort on neuropsychological tests (Binder et al., 
1998; Criswell et al., 2010; Dodrill, 2008; Preiss, Kramska, & Vojtech, 2012; Strutt et al., 
2011a). 
Alternatively, some investigators have suggested that the inconsistency in 
neuropsychological findings for PMD patients across studies may be the product of 
traditional, yet inappropriate, methodology of indiscriminately grouping all symptom 
phenotypes together in statistical analyses (Hill & Gale, 2011; Stone, Sharpe & Binzer, 
2004).  Thus, it may be the case that examination of general profiles in all PMD patients 
has potentially obscured specific differences between subgroups, which may actually be 
more homogeneous with respect to neuropsychological functioning as well as underlying 
psychopathology.  As such, the establishment of unique psychosocial and neurocognitive 
9 
profiles within subgroups could potentially improve differential diagnostic accuracy as 
well as subsequent treatment planning for this patient population, and perhaps, facilitate 
specification of the etiopathogenesis of this debilitating condition (Bodde et al., 2013; 
Magaudda et al., 2011).   
As previously mentioned, the few studies that have attempted to compare PMD 
subgroups have yielded significant results.  For instance, research conducted by Hopp, 
Anderson, Krumholz, Gruber-Baldini, & Shulan (2012) suggests that greater gender 
heterogeneity and different clinical manifestations (e.g., altered consciousness, episodic 
symptoms, and lateralization) may characterize patients with other PMD phenotypes as 
compared to those with PNES.  Additional differences observed have included a younger 
age of onset, higher rates of reported trauma and environmental stressors, as well as 
greater borderline personality features and external control orientation associated with 
PNES patients than those with other PMD phenotypes (Oto, 2008; Stone et al., 2004).  
Furthermore, emerging evidence suggests that subtype classification of PNES may have 
relevant clinical and research implications (Griffith, Smith, Schefft, Szaflarski, & 
Privitera, 2008), and thus various classification schemas have been proposed (Bodde et 
al., 2012; Cragar, Berry, Schmitt, & Fakhoury, 2005; Drury, 2000; Griffith et al. 2007; 
Henry & Drury, 1998; Hill & Gale, 2011; Magaudda et al., 2011; Selwa et al., 2000).  
Unfortunately, however, such studies have yet to be replicated and a consensus has yet to 
be reached. 
Neuroanatomical Correlates 
A recent boom in neuroimaging studies with PMD patients has begun to shift our 
conceptualization of these motor manifestations from a purely psychological theory to a 
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broader neurobiological model (Hallett, 2010; Lang & Mula, 2013; Mayor, 2012).  For 
instance, a recent study conducted by Labate and colleagues (2012) provides evidence 
that several structural brain abnormalities are present in patients with PNES, including 
abnormal cortical atrophy of the motor (i.e., precentral gyrus) and premotor (i.e., superior 
frontal gyrus and paracentral gyrus) regions in the right hemisphere, as well as the 
cerebellum bilaterally.  Moreover, a significant inverse relationship was observed 
between the aforementioned premotor regions and the severity of depressive 
symptomatology (Labate et al., 2012).  Such findings are consistent with a number of 
functional neuroimaging studies revealing hypoactivation of the primary motor cortex 
contralateral to the affected limb in PMD patients with both hypokinetic and hyperkinetic 
motor manifestations (Burgmer et al., 2006; Cojan, Waber, Curruzzo, & Vuilleumier, 
2009; De Lange, Roelofs, & Toni, 2007; Marshall, Halligan, Fink, Wade, & Frackowiak, 
1997; Schrag et al., 2013; Stone et al., 2007).  The majority of neuroimaging studies have 
also identified functional abnormalities in prefrontal cortical areas (e.g., ventromedial 
prefrontal cortex [VMPFC], dorsolateral prefrontal cortex [DLPFC], orbitofrontal cortex 
[OFC]), limbic structures (e.g., amygdala, anterior cingulate cortex [ACC]), and other 
subcortical regions (e.g., basal ganglia, thalamus), as well as specific abnormalities in 
functional connectivity between such neuroanatomical regions (Van der Kruijs et al., 
2012; Voon et al., 2010a, b).   
Although the majority of research in this area has focused on psychogenic 
paralysis, and the variegated sample composition and methodology of each study make it 
difficult to provide direct comparisons, altogether the available data seem to implicate 
abnormal cortico-limbic interactions in PMDs.  Thus, it may be the case that both 
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hyperactivation of limbic areas in response to emotionally arousing stimuli and functional 
disconnection of motor areas from the inhibitory control of the prefrontal cortex are 
involved in the production of psychogenic motor phenomena (Labate et al., 2012; Mula, 
2013).  Additionally, the abnormalities observed in the thalamus and basal ganglia may 
contribute to the production of psychogenic motor manifestations via striato-thalamo-
cortical premotor loops (Vuilleumier et al., 2001), as well as alterations in motor 
intention or attention (Cummings, 1993; Edwards & Bhatia, 2012; Schrag et al., 2013).  
Moreover, such functional abnormalities along with aberrations in several cortical 
regions may contribute to cognitive dysfunction in various domains via disruption of 
cortico-striatal-thalamo-cortical loops, including executive dysfunction (DLPFC), 
impaired attention (dorsal ACC), emotion dysregulation (ventral ACC), and impulsivity 
or compulsivity (OFC; Stahl, 2008).  
Neurobiological Markers 
Considering that PMDs are conceptualized as “functional” or “stress related” 
movement disorders, the paucity of research investigating stress-related phenomena in 
this patient population is striking.  However, in addition to neuroimaging data, emerging 
evidence suggests that PMD patients may have distinguishing neurobiological features 
previously shown to be associated with abnormal responses to stress (Bakvis et al., 2009; 
Bakvis et al., 2010; La France, Leaver, Stopa, Papandonatos, & Blum, 2010).  For 
instance, a recent study conducted by Bakvis et al. (2009) found decreased levels of basal 
heart rate variability in PNES patients, who also demonstrated a positive attentional bias 
for fear-inducing stimuli (suggesting a hypervigilant state), which was significantly 
related to self-reported trauma.  In a later study, Bakvis et al. (2010) demonstrated 
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significantly greater basal diurnal cortisol levels in PNES patients compared to healthy 
controls, which was significantly associated with reports of sexual trauma and 
independent of the acute occurrence of seizures, current depressive symptoms, 
medications, and smoking.  Additionally, research by La France and colleagues (2010) 
identified significantly lower levels of plasma brain-derived neurotrophic factor (BDNF) 
in PNES patients compared to healthy controls.   
Thus, extant neurobiological data seem to implicate dysregulation of the 
hypothalamic-pituitary-adrenal axis (HPA-axis), which, along with limbic system 
structures, are particularly sensitive to stress exposure during early development.  
Considering the higher incidence of traumatic episodes and chronic anxiety in PMD 
patient populations, as well as the greater tendency of these patients to perceive such 
events as subjectively more distressing, it seems likely that stress-related HPA-axis 
dysregulation may play a role in the etiopathogenesis of this condition.  Hence, it may be 
the case that PMD patients experience overwhelming or chronic stress during 
development, leading to stress-sensitized neuronal circuits that may potentially be 
activated even without exposure to new stressors (Stahl, 2008).  The decompensation of 
these vulnerable circuits may lead to the production of an abnormal stress response not 
unlike that proposed for anxiety disorders, wherein normal stress hormones are all 
released, but they all remain persistently elevated rather than recovering rapidly as they 
would during a normal/adaptive stress response.  The persistent elevation of 
glucocorticoids can produce hippocampal atrophy, changes in gene expression, 
disinhibition of the HPA-axis, and can increase the risk of subsequent affective 
disturbances—including the development of anxiety and mood disorders (Stahl, 2008).  
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Such neurobiological abnormalities could also account for the observed structural and 
functional neural changes observed in PMD patients.  
Moreover, excessive secretion of norepinephrine from the locus coeruleus in 
response to stress can produce alterations in cognitive functioning (via the prefrontal 
cortex), symptoms of anxiety, panic attacks and hyperarousal (via the amygdala), as well 
as motor disturbances such as tremor and changes in sympathetic discharge and 
parasympathetic tone (via the brainstem; Benarroch, 2009; Stahl, 2008).  This increase in 
norepinephrine output can also inhibit serotonin release via presynaptic alpha 2 
heteroreceptors located on the nerve terminals of serotonin neurons.  A deficiency in 
serotonin availability would result in diminished activation of signal transduction 
cascades initiated by this neurotransmitter, and therefore, decreased production of BDNF, 
which can lead to a loss of synapses as well as entire neurons via apoptosis.  Serotonergic 
projections from brainstem neurotransmitter centers also exert an inhibitory effect on the 
amygdala, and thus, loss of inhibitory input to this region could contribute to the chronic 
anxiety observed in PMD patients (Stahl, 2008).  Additionally, dysregulation of the 
amygdala may be related to the functional abnormalities exhibited in prefrontal regions of 
PMD patients, as the amygdala has reciprocal connections with the ACC, OFC, 
hypothalamus, thalamus, hippocampus and several brainstem nuclei, which are all 
involved in the neurobiology of fear.  Finally, changes in both norepinephrine and 
serotonin may be related to the functional abnormalities of the DLPFC documented in 
PMD patients, as both of these neurotransmitters are involved in the regulation of a 
cortico-striatal-thalamo-cortical loop originating in this area of the PFC and are believed 
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to mediate worry-related symptoms in anxiety disorders, including catastrophic thinking, 
apprehensive expectation, obsession, and anxious misery (Stahl, 2008).  
An additional mechanism of action potentially implicated in anxiety disorders 
involves deficient GABA and serotonergic input to the amygdala, which in turn, could 
lead to diffuse glutamate excitotoxicity.  If as some researchers suggest (Van Merode et 
al., 2004), chronic anxiety is indeed a condition conferring risk to the initial development 
of psychogenic movements, then perhaps the etiopathogenesis involves the destruction of 
cortical pyramidal neurons via such mechanisms.  However, even in the absence of 
neuronal damage such neurochemical abnormalities would, nevertheless, alter the 
regulatory input to cortical pyramidal neurons causing them to be “out of tune” (Stahl, 
2008).  Moreover, such alterations could lead to dysregulation of descending cortical 
projections, impaired functional connectivity between multiple regions, and ultimately 
the production of cognitive, affective, and perhaps even motor symptoms as well. 
Integration of Previous Research 
 Altogether, the available data seem to suggest a diffuse pattern of functional and 
perhaps structural neuronal changes associated with psychogenic movement disorders, 
and while principle causative factors remain elusive, converging evidence seems to 
suggest that frontal lobe dysfunction may play a critical role.  If this is indeed the case, 
then given our current understanding of frontal lobe function, PMD patients should 
exhibit a disruption in attention (dorsal ACC), executive functioning and problem-solving 
(DLPFC), as well as emotional processing (VMPFC) and affective regulation (ventral 
ACC). 
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As such, the purpose of the current study is to compare the neuropsychological 
performance, psychological profiles, and comorbid affective symptomatology of PMD 
patients with hyperkinetic motor manifestations.  Therefore, statistical analyses will be 
aimed at (1) testing the validity of the proposed model of frontal lobe pathology and 
stress-related phenomena in PMD patients, (2) clarifying the relationship between 
posttraumatic symptomatology, psychopathology, and neuropsychological functioning in 
this patient population, (3) examining the validity of PMD classification systems 
proposed by previous researchers, and (4) utilizing such information to elucidate 
characteristic differences that may be utilized to facilitate and inform differential 
diagnosis and treatment planning for PMD patients with different clinical presentations.   
In contrast to previous neuropsychological research with PMD patients, which has 
either approached analyses from the theoretical perspective of cognitive functioning in 
the neurological counterparts of PMD subgroups, or has neglected to employ a theoretical 
perspective altogether, statistical analyses in the current study will be guided by the 
aforementioned theory of frontal lobe dysfunction and HPA-axis disinhibition, which the 
extant data seem to implicate in PMD patients.  Considering that both affective distress 
and frontal lobe dysfunction can produce impairments in attention, working memory, and 
executive functioning, it is hypothesized that such deficits will be among the most 
prominent in the current sample.  Additionally, given the toxic effect of stress-related 
hormones on neuroanatomic structures mediating memory, it is expected that PMD 
patients with more severe anxiety symptoms will demonstrate poorer memory 
performance than those with minimal anxiety symptoms.  Finally, with respect to 
subgroup differences, it is hypothesized that patients with more dramatic motor 
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manifestations (i.e., PNES versus other PMDs) will demonstrate greater 
neuropsychological impairments, exhibit more severe psychopathology, and report either 
a greater chronicity or severity of traumatic experiences.   
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Method 
Participants 
 Data collection for the current study was conducted at Baylor College of 
Medicine (BCM) and St. Luke’s Methodist Hospital in Houston, Texas, as well as Martin 
Neurobehavioral Center (MNC) in Tyler, Texas.  Potential participants were identified 
based on previous neurological evaluations and appropriate medical assessments (i.e., 
video-EEG monitoring or adherence to Fahn and Williams criteria) establishing a 
psychogenic diagnosis.  Inclusion criteria included: 1) English-speaking adults; 2) both 
males and females; 3) eighteen to sixty-five years of age.  Exclusion criteria included: 1) 
presence of an underlying organic neurological disorder; 2) current or past psychotic 
symptoms that could interfere with assessment; 3) substance abuse disorder within the 
past six months; 4) traumatic brain injury; 5) unstable medical condition or clinically 
significant abnormal laboratory results; 6) mixed etiologies (e.g., concurrent epilepsy and 
PNES).   
 Altogether, 84 PMD patients were identified as potential participants and 
screened for possible inclusion in the current study.  Of those patients screened, 27 were 
excluded due to age (9), poor English mastery (2), traumatic brain injury (3), 
cerebrovascular accident (4), multiple sclerosis (1), and other comorbid neurological 
conditions (8).  Additionally, eighteen patients declined the initial invitation to participate 
in the current study, and seven patients were scheduled to participate but ultimately did 
not complete the evaluation.  The final sample consisted of thirty-two PMD patients.   
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Each patient’s motor manifestations were characterized based on symptoms documented 
by the neurologist in their electronic medical chart, resulting in the following symptom 
classifications: 16 PNES (50.0%), 2 dystonia (6.3%), 1 bilateral tremor (3.1%), 1 left-
sided tremor (3.1%), 3 right-sided tremor (9.4%), 1 myoclonus (3.1%), 2 gait disturbance 
(6.3%), 2 bilateral tremor and gait disturbance (6.3%), 1 tic and stereotypies (3.1%), and 
3 mixed facial symptoms (e.g., dystonia, tics, orofacial dyskinesia, and blepharospasms; 
9.4%).   
As ten of these patients had previously completed a comprehensive 
neuropsychological evaluation at MNC, their data were obtained via archival review.  
The remaining sample had yet to complete a neuropsychological assessment and were 
therefore evaluated by study investigators, including one participant tested as an inpatient 
at St. Luke’s and twenty-one participants tested as outpatients at BCM.  This assessment 
is not a routine component of standard clinical care for individuals with these diagnoses, 
and thus, the current evaluation was offered as a free service.  The present study was 
approved by the Institutional Review Board at BCM as well as the University of Texas at 
Tyler, and all participants evaluated by study investigators provided informed consent. 
Study Design 
The current study employed a quasi-experimental design, wherein the following 
bi-level quasi-independent variables were utilized to define groups for comparison: 1) 
Motor manifestations (PNES versus other hyperkinetic PMDs); 2) Treatment with 
psychotropic agents versus those without.  Such variables were established through 
review of medical records and clinical interviews conducted with each patient.  These 
groups provided the basis for comparison among multiple dependent variables, including 
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symptom characteristics, psychosocial variables, and performance on the outcome 
measures (described below).  
Outcome Measures 
The following neuropsychological measures were administered and scored 
according to standardized procedures: Montreal Cognitive Assessment (MoCA: 
Nasreddine et al., 2005), a screening tool assessing general mental status; Digit Span 
subtest of the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV: Wechsler, 
2008), a measure of attention and working memory; Wechsler Test of Adult Reading 
(WTAR: Wechsler, 2001), an estimate of premorbid intellectual functioning; Trail 
Making Test, Parts A and B (TMT-A and TMT-B: Reitan, 1992), a measure of 
visuomotor integration and set shifting; Lexical (FAS) and Semantic (Animals) Fluency 
(Heaton, Miller, Taylor, & Grant, 2004; Reitan & Wolfson, 1985), a measure of speeded 
retrieval of exemplars from a phonemic and semantic category, respectively; Test of 
Memory Malingering (TOMM: Tombaugh, 1996) and Rey Fifteen Item Memory Test 
(Rey-15: Rey, 1964; Lezak, Howieson, & Loring, 2004), two measures of symptom 
validity; Wisconsin Card Sorting Test, 64 Card Version (WCST-64: Kongs, Thompson, 
Iverson, & Heaton, 2000), a measure of set-shifting and problem solving ability.   
Participants were also asked to complete the following self-report measures: 
Minnesota Multiphasic Personality Inventory, Second Edition, Restructured Format 
(MMPI-2-RF: Tellegen & Ben-Porath, 2008), a measure of personality, psychopathology, 
and affective symptomatology; Beck Depression Inventory, Second Edition (BDI-II: 
Beck, Steer, & Brown, 1996), a measure of depressive symptoms; Penn State Worry 
Questionnaire (PSWQ: Meyer, Miller, Metzger, & Borkovec, 1990), a measure of 
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cognitive symptoms of anxiety; PTSD Checklist (PTSD-C: Weathers, Litz, Herman, 
Huska, Keane, 1993), a measure of posttraumatic symptomatology; Dissociative 
Experiences Scale, Second Edition (DES-II: Stockdale, Gridley, Balogh, & Holtgraves, 
2002), an assessment of dissociative symptoms; Trauma Symptom Inventory (TSI: 
Briere, 1995), a screening tool for symptoms of posttraumatic stress; and Emotion 
Regulation Questionnaire (ERQ: Goss, & John, 2003), a measure of individual 
differences in emotion regulation strategies.   
The units of measurement for each test typically utilized in clinical practice for 
assessment purposes, were used in the present study to examine group performance.  
Specifically, raw scores were utilized for measures commonly assessed in relation to raw 
score cutoffs (i.e., MoCA, TOMM, Rey-15, BDI-II, PSWQ, PTSD-C, ERQ and DES-II), 
age-adjusted standard scores were used for the WTAR (Wechsler, 2001), and 
demographically adjusted t-scores were used for the TSI (Briere, 1995), MMPI-2-RF 
(Tellegen & Ben-Porath, 2008), WAIS-IV Digit Span (Wechsler, 2008), WCST-64 
(Kongs et al., 2000), TMT and Lexical and Semantic Fluency (Heaton et al., 2004).  
Procedure 
 Neuropsychological evaluations were conducted under the supervision of licensed 
clinical neuropsychologists by psychometricians with formal training in the 
administration and scoring of the aforementioned instruments.  Participants were first 
briefed on the purpose of the study, potential risks and benefits of participating, as well as 
the voluntary nature of their participation.  Verbal feedback was then elicited from 
patients to address any questions or concerns they may have posed and to ensure 
comprehension.  Written consent was subsequently obtained, followed by a clinical 
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interview eliciting pertinent demographic, developmental, medical and psychosocial 
information.  Participants were then administered the aforementioned neuropsychological 
instruments according to the standardized procedures outlined in their respective 
administration manuals.  Following completion of the test battery, participants were 
asked to complete the aforementioned self-report measures to assess their psychological 
functioning.  While administration time varied based on the patient’s functional status, 
the majority of patients were able to complete the assessment within two to three hours.  
The administration order and approximate duration of each component of the assessment 
session is proved in Appendix A.  Additional data regarding each participant’s current 
condition, treatment, and medical history were later obtained via review of medical 
records. 
Statistical Analyses 
 Statistical analyses were conducted via IBM® SPSS version 18.0 for Windows.  
Pearson’s correlations were utilized to examine relationships between variables, while 
multi-dimensional chi-square tests were used to compare categorical variables between 
groups, including demographic variables and classifications of performance on the 
outcome measures.  Given the limited size of the current sample, each continuous 
variable was carefully screened for potential violations of assumptions underlying 
parametric procedures.  Examination of graphical displays (probability-probability plots 
and histograms), values of skew and kurtosis, as well as the Kolmogorov-Smirnov Test 
were used to assess normality, while homogeneity of variance was assessed by means of 
Levene’s Test and other graphical depictions.  Standard statistical transformations as 
outlined by Tabachnick & Fidell (2001) were applied to those variables violating the 
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assumption of normality.  Mann-Whitney tests were utilized to examine between-group 
differences for variables that failed to achieve normalization with statistical 
transformations, while independent sample t-tests were used to compare all other 
continuous variables between groups.  
As age and education are demographic variables known to significantly influence 
performance on neuropsychological tests, these two variables were screened for their 
potential utility as covariates for group comparisons on neurocognitive measures not 
already corrected for both of these demographic variables (i.e., WTAR and WAIS-IV 
Digit Span).  However, when examined as covariates, age was not significantly related to 
either outcome measure, and education was only significantly related to WTAR scores.  
As such, analysis of covariance (ANCOVA) utilizing education as a covariate was used 
to examine between-group differences in WTAR scores, while all other neurocognitive 
measures were assessed via independent sample t-tests and Mann-Whitney tests, as 
outlined above.  Additionally, multiple regression was utilized to examine potential 
predictors of general cognitive impairment for the total sample.  The stepwise method 
was used in this analysis due to the exploratory nature of the present study.  Finally, a 
binary logistic regression analysis was employed to identify potential predictors of group 
membership (i.e., PNES versus other PMD). 
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Results 
Demographic Comparisons 
 A detailed comparison between PNES and PMD groups along demographic 
variables is provided in Table 1.  As shown, no significant between-group differences 
were observed for age at testing, gender, handedness, ethnicity, medical/psychiatric 
history or current treatment.  However, the two groups differed significantly in education, 
U = 73.0, N1 = 16, N2 = 16, p = 0.03, with PMD participants reporting a higher level of 
educational attainment than those in the PNES group.  The two groups also differed 
significantly in marital status, χ2(1) = 8.15, p = 0.04, and functional status, χ2(1) = 6.79, p 
= 0.009, with more PMD participants being married and employed at the time of testing 
than their PNES counterparts. 
While PMD participants tended to report a later age of symptom onset than 
members of the PNES group, this difference did not reach significance.  Additionally, no 
significant differences were observed between groups in self-reported factors 
exacerbating their motor symptoms, which included stress (50.0%), fatigue (21.9%), 
physical pain (21.9%), strong positive or negative emotions (21.9%), heat exposure 
(12.5%), and hormonal changes (6.30%).  However, a significant between group 
difference was observed for onset type, χ2(1) = 6.15, p = 0.01, with a greater proportion 
of PNES patients (75.0%) reporting a sudden onset of their motor symptoms and the 
majority of PMD participants (68.8%) reporting a gradual symptom onset. 
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While the proportion of patients receiving psychotherapy and psychotropic 
medications was nearly equivalent between groups, twice as many PMD as compared to 
PNES patients were taking an antidepressant at the time of testing.  However, no 
significant differences were observed in depressive symptomatology on the BDI-II, 
MMPI-2-RF or TSI between patients receiving antidepressant medications (PNES = 
31.3%; PMD = 62.5%) and those who were not.  Moreover, patients receiving treatment 
with a benzodiazepine at the time of testing (PNES = 50.0%; PMD = 43.8%) 
demonstrated no significant differences in anxiety symptomatology on the PSWQ, 
MMPI-2-RF or TSI than those who were not.  However, those being treated with a 
benzodiazepine demonstrated significantly greater impairment on the TMT-B, t(30) = 
2.33, p = 0.03; Benzodiazepine: M = 31.0, SD = 13.3; No Benzodiazepine: M = 42.7, SD 
= 14.9.  Finally, no significant differences were found in somatic symptomatology 
including pain complaints on the MMPI-2-RF between patients being treated with an 
opiate agonist (PNES = 43.8%; PMD = 56.3%) and those who were not. 
Trauma History 
While the majority of participants reported a history of some form of traumatic 
experience, the frequency of reported sexual abuse was the only traumatic experience 
found to differ significantly between groups, χ2(1) = 4.57, p = 0.03, PNES = 37.5%, PMD 
= 6.30%.  On the TSI, no significant differences were observed between groups in either 
mean T-scores or the frequency of clinical scale elevations.  Additionally, no significant 
between-group differences were observed on the PTSD Checklist or DES-II (Table 2).  
However, while 76.0% of the current sample obtained clinically significant scores on the 
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PTSD Checklist, only 29.2% and 22.2% of participants produced clinically elevated 
scores on the DES-II and dissociation subscale of the TSI, respectively. 
Although PTSD Checklist scores accounted for 42.6% of the variance in DES-II 
total scores, the former measure demonstrated a stronger relationship with the absorption, 
r = 0.66, p < 0.001, and depersonalization, r = 0.65, p = 0.001, subscales than the 
amnesia, r = 0.41, p < 0.05, subscale of the DES-II.  Alternatively, PTSD Checklist 
scores accounted for 50.2% of the variance in dissociation subscale scores of the TSI, 
which exhibited a stronger relationship with the absorption, r = 0.80, p < 0.001, and 
amnesia, r = 0.64, p = 0.005, subscales than the depersonalization, r = 0.49, p = 0.04, 
subscale of the DES-II. 
Assessment of Personality & Psychopathology 
PNES and PMD participants did not differ significantly in either affective 
symptomatology or emotion regulation strategies (Table 3).  On the BDI-II, 43.4% of the 
total sample obtained scores in the minimal range, while 16.7% reported mild and 40.0% 
moderate to severe depressive symptoms, respectively.  Clinical classifications on the 
PSWQ were as follows: 28.0% low worry, 40.0% moderate worry, and 32.0% high 
worry.  Examination of ERQ subscale scores revealed 64.0% of participants utilize 
reappraisal over suppression strategies, which was also not found to differ significantly 
between groups. 
On the MMPI-2-RF, no significant between-group differences were observed in 
mean T-scores, with the exception of the Restructured Clinical (RC) scale 3: Cynicism, 
t(24) = 2.34, p = 0.03; PNES: M = 54.7, SD = 8.91; PMD: M = 45.6, SD = 10.5.  A 
comparison of the RC scale profiles of PNES versus other PMD participants is depicted 
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in Figure 1.  In terms of the frequencies of clinical scale elevations, a significantly higher 
proportion of PMD participants produced elevated scores on the Negative 
Emotionality/Neuroticism scale, χ2(1) = 4.21, p = 0.04, PNES = 6.30%, PMD = 43.8%, 
while a significantly greater number of PNES patients obtained clinically elevated scores 
on the Suicidal Ideation scale, χ2(1) = 5.11, p = 0.02, PNES = 18.8%, PMD = 0.0%. 
 PNES and PMD participants did not differ significantly on the Anxiety scale of 
the MMPI-2-RF.  However, an examination of the differences between participants’ with 
clinically elevated scores on the Anxiety scale versus those within normal limits, 
indicated that the former group reported significantly greater symptoms of depression, 
BDI-II: t(30) = -3.11, p = 0.005, dissociation, DES-II: t(30) = -2.50, p = 0.02, and 
posttraumatic symptomatology, PTSD Checklist: t(30) = -5.76, p < 0.001.  These 
individuals also obtained significantly lower Memory subscores on the MoCA, t(30) = 
3.42, p = 0.002, than those with Anxiety scores within normal limits. 
Assessment of Neuropsychological Functioning 
 All participants obtained valid scores on two measures of suboptimal effort, 
including the TOMM (PNES: M = 49.2, SD = 1.60; PMD: M = 49.9, SD = 0.26) and Rey-
15 (PNES: M = 12.7, SD = 0.90; PMD: M = 14.4, SD = 1.24), indicating that they put 
forth valid effort during their neuropsychological assessment (Table 4).  While group 
mean WTAR scores were in the average range, the mean MoCA total scores for both 
groups were in the impaired range, with approximately 75.0% of PNES and 56.3% of 
PMD participants demonstrating deficient performance on this measure.  Although no 
significant between-group differences were observed for MoCA total scores, PMD 
participants significantly outperformed their PNES counterparts on the Attention subscale 
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of the MoCA, t(30) = -2.88, p = 0.007.  MoCA performance by domain in comparison to 
the extant normative data is provided for the combined sample in Figure 2. 
 Mean Digit Span total scores for PNES and PMD participants were in the low 
average and average range, respectively.  However, significantly more PNES (37.5%) 
than PMD (6.25%) participants obtained Digit Span total scores in the impaired range, 
χ2(1) = 5.04, p = 0.03.   TMT group means varied from low average to mildly impaired 
and did not differ significantly between groups.  While PMD and PNES participants 
demonstrated comparable semantic fluency performance, their lexical fluency scores 
differed significantly between groups, t(30) = -3.44, p = 0.002, with PNES participants 
evidencing mild to moderate impairment on this measure in comparison to the low 
average classification of the PMD group’s performance.  Additionally, both PNES and 
PMD group means were in the low average range for WCST-64 total and perseverative 
errors, while PNES patients demonstrated significantly more perseverative responses than 
PMD participants on this measure, t(30) = -3.87, p = 0.001.  The neuropsychological 
profile of the combined groups in relation to demographically corrected normative data is 
provided in Figure 3. 
 A linear regression analysis employing the stepwise method was utilized to 
identify potential predictors of general cognitive impairment as evidenced by 
performance on the MoCA.  Only variables demonstrating a significant relationship with 
the outcome measure at p < 0.01 and having a theoretical basis for inclusion were used as 
independent variables for the analysis (i.e., years of education, BDI-II and PTSD 
Checklist total raw scores, WCST-64 perseverative errors and MMPI-2-RF Psychoticism 
scale T-scores).  As a result, the first step yielded a significant model, F(1, 23) = 15.4, p 
28 
= 0.001, with only PTSD Checklist scores identified as a significant predictor and 
accounting for 38.5% of the variance, Adjusted R2 = 0.385.  However, in the second and 
final step, a significant model emerged, F(2, 23) = 14.8, p < 0.001, with both years of 
education, β = -0.46, p = 0.007, and PTSD Checklist scores, β = 0.45, p = 0.007, 
identified as significant predictors of MoCA total scores.  The final model explains 
54.6% of the variance in the population, Adjusted R2 = 0.546. 
Exploratory Analyses  
 Given the small sample size of the current study, a conservative approach was 
adopted in subsequent analyses to identify potential predictors of group membership—
utilizing only variables with significant between-group differences at p < 0.01.  Based on 
this criterion, two significant models were generated by means of binary logistic 
regression analyses.  The first model included functional status, MoCA Attention 
subscale scores, WCST-64 perseverative responses and lexical fluency T-scores, with the 
combination of these four variables significantly predicted group membership, omnibus 
χ2(4) = 21.8, p < 0.001.  The model accounted for between 52.8% and 70.6% of the 
variance in motor symptom group membership, with 86.2% of the total sample correctly 
classified.  Separately, however, only functional status and WCST-64 perseverative 
responses were statistically significant predictors (p < 0.05).  A second model was 
generated consisting of functional status and WCST-64 perseverative responses.  This 
combination of variables was also found to be statistically significant, omnibus χ2(2) = 
20.8, p < 0.001, with both variables identified as significant predictors of group 
membership (p < 0.05).  This second model accounted for 47.8 – 63.7% of the variance in 
group membership, with 75.0% of both groups correctly classified.  These findings are 
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considered preliminary, however, and must be interpreted with caution given the limited 
sample size. 
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Discussion 
The present study was undertaken to advance the current conceptualization of 
hyperkinetic psychogenic movement disorders through an examination of psychological 
and neuropsychological functioning of increasingly homogeneous clinical phenotypic 
groups.  Unlike previous investigations approaching assessment from either an 
atheoretical perspective or a model of functioning established in neurological disorders 
with similar clinical presentations, the neurocognitive and psychosocial variables 
examined in the present study were guided by a theoretical lens of frontal lobe pathology 
and informed by previous neuroimaging studies with this patient population.  While the 
results of the present study are consistent with previous investigations observing a higher 
prevalence of affective and posttraumatic symptomatology in this patient population as 
compared to the general population (Fizman et al., 2004; Hallett et al., 2006), the current 
findings also suggest that patients with PNES and other PMDs demonstrate specific 
neurocognitive deficits mediated by frontal lobe structures in the context of average 
premorbid intellectual functioning and the provision of valid effort during 
neuropsychological assessment. 
Frontal Lobe Pathology in PMD 
Considering that both affective distress and frontal lobe dysfunction have been 
shown to produce impairments in attention, working memory, and executive functioning  
(Lezak et al., 2004), it was hypothesized that such deficits would be among the most 
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prominent in the current sample.  Indeed, the results of the present study are generally 
consistent with this hypothesis as the combined sample, including both PNES and other 
PMD patients, demonstrated moderately impaired performance in the attention and 
abstraction domains of the MoCA, while their visuospatial/executive scores were low 
average and their scores in all other domains were in the average range.  The mean 
lexical fluency performance for the total sample fell in the mildly impaired range, while 
performance on other measures of language functioning were within normal limits.  
Simple auditory attention as assessed by the WAIS-IV was generally in the low average 
range, while simple visual attention and tracking skills demonstrated on TMT-A were 
mildly impaired.  On a complex visual attention and tracking task requiring flexibility of 
thought and motor sequencing ability (i.e., TMT-B), the current sample also 
demonstrated mildly impaired performance.  Finally, on a more complex measure 
assessing cognitive flexibility, set shifting and problem solving abilities (i.e., WCST-64), 
the current sample demonstrated performance in the low average range.  While clinically 
significant levels of anxiety and depressive symptoms were observed in both PNES and 
other PMD participants, measures of affective symptomatology failed to demonstrate 
utility in predicting neurocognitive performance.  Alternatively, both education level and 
posttraumatic symptoms as assessed by the PTSD-Checklist were identified as significant 
predictors of MoCA total scores, with lower levels of education and more severe 
posttraumatic symptoms being associated with greater impairments in general cognitive 
status (discussed further below).  
The present findings appear to be consistent with data from previous 
neuroimaging studies implicating functional abnormalities in several prefrontal cortical 
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regions (Cojan et al., 2009; DeLange et al., 2010; Marshal et al., 1997; Schrag et al., 
2013; Spence et al., 2000; Stone et al., 2007; Voon et al., 2010a, b).  Specifically, the 
poor lexical fluency, problem-solving and response inhibition demonstrated by PMD 
participants in the current study may be suggestive of abnormal information processing in 
the DLPFC (Shallice & Burgess, 1991; Stahl, 2008), while the emotional dysregulation 
characteristic of this patient population and also observed in the present study would 
seem to implicate VMPFC dysfunction (Cojan et al., 2009; Lezak et al., 2004).  
Additionally, the attentional disturbances and affective dysregulation demonstrated by 
PMD patients in the present study may be indicative of abnormal information processing 
in the dorsal and ventral ACC, respectively (Stahl, 2008).  Along with the causal 
relationship observed between posttraumatic symptomatology and general cognitive 
impairment, these findings would seem to provide further support for the proposed model 
of frontal lobe dysfunction in PMD involving abnormal cortico-limbic interactions.  In 
addition, such disruptions in higher-order functions may account for the inconsistent 
findings demonstrated across neuropsychological investigations with this patient 
population, as such prefrontal areas subserve functions that facilitate memory (e.g., 
learning and retrieval strategies, organizational approaches, consolidation, etc.) and play 
a principal role in inhibiting interference from competing stimuli (Lezak et al., 2004).   
Etiological Considerations & Conceptual Implications 
Given that neurobiological research has demonstrated elevated cortisol levels in 
this patient population (Bakvis et al., 2010) and persistently elevated glucocorticoids are 
known to exert a toxic effect on neuroanatomic structures mediating memory, it was 
hypothesized that PMD patients with more severe symptoms of anxiety would 
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demonstrate poorer performance on measures of memory than those with minimal 
anxiety symptoms.  The present findings are consistent with this premise, as participants 
with clinically elevated scores on the anxiety scale of the MMPI-2-RF demonstrated 
significantly poorer performance on the memory subscale of the MoCA than patients 
reporting sub-clinical symptoms of anxiety.  As would be expected given the high rates 
of comorbidity frequently observed between such conditions (Hallett et al., 2006), these 
patients also reported significantly greater depressive and dissociative symptoms, as well 
as posttraumatic symptomatology.  While the prevalence of trauma symptoms observed 
in the present study is consistent with previous research (Fizman et al., 2004), the 
stronger association observed between posttraumatic symptomatology and the absorption 
and depersonalization subscales of the DES-II in comparison to other dissociative 
sequelae assessed by this measure, would seem to suggest that a more clinical form of 
dissociation may characterize this patient population (Putnum et al., 1996).  
Altogether, such findings would appear to lend credence to the notion of HPA-
axis dysregulation and the conceptualization of this form of psychogenic illness as a type 
of anxiety disorder, or perhaps more specifically a subtype of PTSD, as has been 
suggested by previous investigators (Brewin, Andrews, Rose, & Kirk, 1999; Bryant & 
Harvey, 2000; Fizman et al., 2004).  This line of reasoning stems from investigations of 
the neuronal circuitry underlying responses to script-driven trauma imagery in PTSD 
patients (Hopper, Frewen, Van der Kolk, & Lanius, 2007; Lanius et al., 2002), in which 
two distinct subgroups have been identified: one consistent with the DSM definition 
emphasizing hyperarousal; and another principally characterized by dissociative 
symptoms.  Such research indicates that PTSD patients in the latter subgroup demonstrate 
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a dissociative response to fear-inducing stimuli, which is neurophysiologically 
characterized by increased activation of the medial prefrontal cortex and anterior 
cingulate gyrus along with increased inhibition of amygdala processing and decreased 
activation of the right inferior frontal cortical region associated with movement inhibition 
(Aron & Poldrack, 2005; Hopper et al., 2007; Lanius et al., 2002).  Moreover, factors 
similar to those reported by PMD patients in the current study (e.g., stress, strong 
emotions, etc.) have also been reported to exacerbate the dissociative symptomatology in 
such patients (Sierra, & Berrios, 1998).  Although research with PMD patients has yet to 
employ such paradigms, the overlap between functional abnormalities observed in this 
patient population and the proposed dissociative subtype of PTSD provide compelling 
evidence for a cortico-limbic disconnection conceptualization of psychogenic illness. 
Utility of PMD Phenotypic Classifications 
With respect to subgroup differences, it is was hypothesized that patients with 
more dramatic motor manifestations (i.e., PNES versus other PMDs) would demonstrate 
greater neuropsychological impairments, exhibit more severe psychopathology, and 
report either a greater chronicity or severity of traumatic experiences.  The present 
findings are partially consistent with these predictions, as patients with other hyperkinetic 
motor symptoms generally outperformed their PNES counterparts across 
neuropsychological measures.  However, the only neurocognitive discrepancies between 
motor groups to reach statistical significance were on measures assessing simple auditory 
attention, lexical fluency and response inhibition.  While the psychological profiles of 
PNES and other PMD participants were generally comparable and clinically depressive 
symptoms were observed in both groups, a significantly greater prevalence of negative 
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emotionality and cynicism was observed in patients with other hyperkinetic PMDs.  Such 
findings seem to suggest that the depressive symptoms experienced by these patients may 
be more accurately characterized as symptoms of increased negative affect, which are 
theoretically related to serotonergic and noradrenergic dysfunction as opposed to 
symptoms of decreased positive affect, which entails a greater involvement of 
dopaminergic dysregulation (Stahl, 2008).  Alternatively, a significantly higher 
prevalence of suicidal ideation was reported by PNES patients, which may be suggestive 
of more severe abnormalities in serotonergic projections from brainstem raphe nuclei to 
the amygdala, VMPFC and OFC (Stahl, 2008). 
Consistent with previous findings (Stone et al., 2004), participants with other 
hyperkinetic motor manifestations tended to be older, more educated, and report a later 
age of symptom onset than PNES patients—although only the educational discrepancy 
reached statistical significance.  While similar rates of self-reported trauma and 
posttraumatic symptomatology were observed in both groups, PNES patients reported a 
significantly higher prevalence of sexual abuse as compared to patients with other 
hyperkinetic PMDs.  Moreover, in comparison to the PNES group, a significantly greater 
number of PMD patients were married and employed at the time of testing.  While 
functional status and response inhibition skills were observed to significantly predict 
group membership, it may be the case that greater executive deficits characterize PNES 
versus PMD patients resulting in a diminished capacity to navigate social interactions and 
appropriately modify behavioral strategies according to environmental feedback. 
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Treatment Implications 
The results of the present study are also consistent with the well-established fact 
that effective treatment modalities for this patient population are decisively lacking.  
While the proportion of patients receiving psychotherapy and psychotropic medications 
was comparable between PNES and other PMD patients, those receiving specific 
psychotherapeutic agents failed to demonstrate characteristic advantages over those not 
receiving similar treatment at the time of testing.  Specifically, patients taking 
antidepressant medications reported depressive symptoms comparable to those not 
receiving such psychotropic agents, while the subset of patients receiving treatment with 
a benzodiazepine at the time of testing demonstrated anxiety symptoms comparable to 
those not receiving such treatment.  Finally, no marked decrements in somatic 
symptomatology, including pain complaints, were observed in those being treated with an 
opiate agonist at the time of testing in comparison to those receiving no such treatment.  
Although a potential confounding variable may include symptom severity prior to 
treatment, such findings, nevertheless, raise concerns regarding the efficacy of these 
psychopharmacological agents with this patient population and would seem to reinforce 
the need for future research investigating the utility of these pharmacological 
interventions. 
Considering the traditional conceptualization of PMD as a purely “functional” 
rather than “organic” condition, cognitive behavioral therapy (CBT) is currently the 
treatment of choice for this patient population (Goldstein et al., 2010; LaFrance et al., 
2009).  However, given that CBT has been found to produce neurochemical changes in 
patients with mood and anxiety disorders, the remediation of motor symptoms in PMD as 
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a result of such therapeutic intervention may simply be due to an improvement in 
affective symptomatology (DeRubeis, Siegle, & Hollon, 2008).  Consistent with such 
hypotheses are the results yielded from recent psychopharmacological studies employing 
the antidepressants sertraline (Zoloft) and venlafaxine (Effexor) with PNES patients.  Of 
interest, however, is the fact that despite both drugs producing variable decreases in the 
frequency of non-epileptic seizures experienced by these patients, only the latter 
produced significant improvement in PNES patients’ affective symptomatology 
(LaFrance et al., 2010; Pintor et al., 2010).  Given that no appreciable reduction in seizure 
frequency was achieved with the additional psychopharmacological actions of 
norepinephrine reuptake, such findings would seem to implicate serotonergic 
abnormalities in the production of psychogenic movements and suggest a viable target for 
research into more efficacious drug therapies for PMD patients.  
Moreover, despite notable improvements in affective functioning and somatic 
complaints, CBT has failed to demonstrate any appreciable effects on functional status in 
patients with psychogenic illness (Thomas & Jankovic, 2004).  In the present study, 
however, significant differences were observed between PNES and other PMD patients 
with respect to functional as well as marital status.  When considered in the context of 
previous research demonstrating greater borderline personality features in this PMD 
subgroup (Stone et al., 2004), such findings may be suggestive of greater disturbances in 
interpersonal and communication skills.  If this is indeed the case, then perhaps 
integrating interpersonal/social therapeutic techniques into a CBT framework may be a 
beneficial approach to treating PNES patients.  In addition, only PNES patients in the 
present study reported clinically significant symptoms of suicidal ideation, suggesting the 
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need for more aggressive therapeutic interventions with this motor subgroup, which may 
include recently developed CBT models specifically tailored to reduce suicidal 
ideation/behavior (Berk, Henriques, Warman, Brown, & Beck, 2004) and perhaps off-
label use of psychopharmacological agents with demonstrated efficacy in reducing 
suicidal ideation in other clinical populations (e.g., lithium).   
Alternatively, patients with other hyperkinetic PMDs demonstrated significantly 
greater negative emotionality and neuroticism, which previous research has found to be 
associated with general deficits in attentional control including difficulty disengaging 
attentional resources from negatively valenced stimuli (Bredemeier, Berenbaum, Most, & 
Simons, 2011).  As such, perhaps patients with similar hyperkinetic symptoms may 
receive particular benefit from therapeutic interventions incorporating biofeedback 
training, in which patients learn to restructure targeted patterns of brainwaves through the 
provision of information on their cortical electrical activity.  Considering that similar 
treatment paradigms have been successfully employed in clinical populations with similar 
symptoms, including posttraumatic stress disorder (Morina et al., 2012; Zotev, Phillips, 
Young, Drevets, & Bodurka, 2013), major depressive disorder (Choi et al., 2010; Sacchet 
et al., 2013), fibromyalgia (Kayiran, Dursun, Dursn, Ermutlu, & Karamürsel, 2010), 
generalized anxiety disorder (Kerson, Sherman, & Kozlowski, 2009), and attention 
deficit disorder (Thompson & Thompson, 1998), this novel approach to treating 
psychogenic illness appears promising.  However, given the apparently diminished 
capacity of PNES patients to modify behavioral strategies appropriately in response to 
environmental cues, these patients may be less likely to benefit from this form of 
treatment. 
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Diagnostic Considerations 
Over time, the American Psychiatric Association (APA) has come to occupy a 
position of considerable power and influence within the field of mental health, as their 
Diagnostic and Statistical Manual of Mental Disorders (DSM) currently guides the 
direction and scope of clinical practice as well as scientific inquiry (Eriksen & Kress, 
2005).  During the preparation of this manuscript, the legacy of the APA was extended 
with the publication of the long anticipated and sharply criticized DSM, Fifth Edition 
(DSM-V: APA, 2013).  According to the APA, their current nosological system is based 
on clinical utility, is grounded firmly on empirical research, and provides a simple and 
succinct format which facilitates communication among professionals (APA, 2000; APA, 
2013; Jablensky, 2009; Spritzer, 2005).  Advocates of this clinical instrument further 
assert that the descriptive phenomenological approach characterizing the current 
categorical scheme of the DSM results in highly reliable identification of mental 
disorders, which enables an accurate comparison of available treatment modalities and 
identification of psychosocial correlates, and is the only viable classification scheme at 
present, because there is currently not enough known about the etiology and 
pathophysiological processes underlying mental disorders to structure the diagnostic 
compendium according to etiology (APA, 2000; APA, 2013; Spitzer, 2005; Widiger & 
Mullins-Sweatt, 2007). 
 However, the validity of the current system is dubious at best, as politics and 
financial conflicts of interest have and continue to play a stronger role in its development 
and revision rather than empirical research data (Conner, 2004; Eriksen & Kress, 2005; 
Frances, 2012).  In fact, the DSM appears almost resistant to scientific evidence as it 
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retains its former classification schema despite advancements in technology enabling the 
identification of biological substrates associated with a wide variety of mental health 
conditions, including psychogenic illness (Anderson, Maes, & Berk, 2012; Labate et al., 
2012; McHugh, 2005; Tagay, Schlegl, & Senf, 2010).  While the APA purportedly 
considered reclassification of PMD in the new DSM-V, this condition continues to share 
a diagnostic category with conditions previously referred to as somatization, 
hypochondriasis, and factitious disorder (APA, 2013)—thereby retaining the inherent 
implication of either interpretive bias or conscious intent as causal mechanisms 
underlying PMD.  In contrast to such stark resistance to change, research linking PMDs 
with dissociative pathology has been sufficiently convincing such that the ICD-10 now 
catalogues PMD as a dissociative type of condition (Brown, Cardena, Nijenhuis, Sar, & 
Van der Hart, 2007; World Health Organization, 1992).  Regardless of the specific 
organizational scheme advocated, the fact remains that the DSM-V’s current 
classification of PMD is inconsistent with accumulating research demonstrating 
neurobiological underpinnings of PMD symptomatology.  Such dissonance between a 
requisite clinical instrument and existing empirical data will continue to hinder 
advancements with this clinical population as the development of increasingly efficacious 
therapeutic interventions is dependent upon an accurate conceptualization of underlying 
pathology—neither of which the current nosological system provides.  Only through 
restructuring the classification system to actually conform to empirical data will the field 
of psychiatry effectively redirect research efforts toward uncovering pathogenic 
processes, and thereby advance beyond reliance on a mere field guide that may be 
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reliable but not necessarily valid (Eriksen & Kress, 2005; Zalaquett, Fuerth, Stein, Ivey, 
& Ivey, 2008). 
Limitations & Future Directions 
Given the small sample size and the high number of statistical comparisons 
utilized in the current study, these findings must be interpreted with caution.  It must also 
be acknowledged that the limited size of the current sample prevented further subdivision 
of the other hyperkinetic PMD group, which may have potentially obscured 
psychological and neurocognitive differences between more homogeneous motor 
subgroups (e.g., tremor versus gait disturbances, etc.).  Additionally, the sample 
employed may have consisted of more severe cases of PMD as these individuals were 
seen at specialized centers, to which they were likely referred by previous healthcare 
professionals.  Future research should strive to investigate a larger sample and provide 
comparisons between more homogeneous motor subgroups, while also specifically 
requesting information concerning previous psychogenic diagnoses as well as the 
frequency and type of previous therapeutic interventions undertaken.   
As the development of psychogenic illness is predicated upon an inability to 
regulate emotions and available data suggests abnormalities in neuronal networks 
subserving affective regulation, future investigations should also undertake a more 
comprehensive assessment of the affective expression and emotion regulation strategies 
employed by PMD patients.  Moreover, given extant data implicating abnormalities in 
serotonergic projections from brainstem neurotransmitter centers to prefrontal cortical 
and limbic structures, future avenues of research may include controlled drug trials as 
well as genomic testing to identify potential genotypes for the serotonin transporter and 
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other receptors that may convey greater risk to decompensation of cortical circuitry upon 
exposure to environmental stressors.  Along those same lines, future research should be 
undertaken to examine stress hormones, including cortisol levels, and plasma BDNF in 
relation to abnormal cortico-cortical and cortico-limbic connectivity in PMD patients, as 
some research suggests that chronic glucocorticoid exposure may lead to the 
downregulation of serotonergic 1A receptors, which play a critical role in regulating 
serotonergic neurotransmission, and by extension, the development and maintenance of 
neural circuits fostered by BDNF synthesis (Savitz, Lucki, & Drevets, 2009; Stahl & 
Briley, 2004).  Finally, longitudinal research tracking the progression of neurobiological 
markers as well as the observed functional abnormalities in relation to normal age-related 
atrophy may also be beneficial. 
Closing Remarks 
In sum, PMD represents a complex and severe form of psychopathology that is 
currently poorly understood.  As a shorter duration of motor symptoms has been 
associated with a better prognosis (Hallett et al., 2006), early detection and treatment of 
this condition is required.  However, if as has been suggested (Stone et al., 2004), the 
only feature unifying these forms of psychogenic illness is the imitation of neurological 
disorders, then further research with mixed samples confounded under the general label 
of PMD or even “pseudoseizures” will continue to yield inconsistent results and the 
therapeutic interventions, subsequently developed from a poor understanding of the 
etiology of such afflictions, will remain less than comprehensive.  While “psychogenic 
movement disorders” has long served as an umbrella term for patients with psychological 
disturbances in the presence of medically unexplained symptoms, the results of the 
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current study suggest that PMD patients with different hyperkinetic motor manifestations 
do not represent a unitary group, but instead, may be characterized by subtle differences 
that could have important implications for uncovering the etiopathogenesis of this 
debilitating condition as well as developing increasingly efficacious treatment strategies 
for this clinical population.  As such, future research is needed to determine the origin of 
such similarities and differences in these forms of psychogenic illness, as well as the 
utility of such characteristics in delineating appropriate therapeutic interventions for 
various PMD subgroups.  
What is clear, however, is that in order to advance scientific understanding and 
treatment of psychogenic illness, research endeavors must be released from the shackles 
of reliable but invalid classification schema that holds fast to outdated conceptualizations 
derived from a theorist relying solely on his faculties of reason and clinical observation in 
an era prior to the advent of modern medicine (i.e., neuroimaging, neurobiological and 
psychopharmacological knowledge).  While clinical correlations may provide utility in 
directing scientific inquiry, it is well-known that correlation is not equivalent to 
causation.  Thus, just as depression is not effectively remediated with the simple 
application of an appetite stimulant and hypnotic agent, so too is psychogenic illness not 
effectively treated from a conceptual standpoint limited to clinical correlations.  Although 
the assumption that somatic manifestations of PMD patients function as an expression of 
underlying psychological distress is supported by research demonstrating that a reduction 
in motor symptoms is typically accompanied by an amelioration of emotional turmoil, the 
fact remains that the causative mechanisms underlying this so-called “conversion” 
process have yet to be identified.  Therefore, future investigators working with this 
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patient population are encouraged to adopt a multi-disciplinary approach employing 
recent technological advances and utilizing theoretical models guided by empirically 
established principles of neurocognitive functioning. 
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Appendix A: Procedural Outline of Assessment Session 
1. Informed Consent (approximately 5-10 minutes) 
2. Clinical Interview (approximately 15-30 minutes) 
3. Administration of Neuropsychological Measures (approximately 45-60 minutes) 
i. Rey Fifteen Item Memory Test (Rey-15) 
ii. Montreal Cognitive Assessment (MoCA) 
iii. Test of Memory Malingering (TOMM) 
iv. Wechsler Test of Adult Reading (WTAR) 
v. Digit Span subtest of the WAIS-IV  
vi. Lexical (FAS) and Semantic (Animals) Fluency  
vii. Trail Making Test, Parts A and B (TMT-A and -B) 
viii. Wisconsin Card Sorting Test, 64 Card Version (WCST-64)  
4. Administration of Self-Report Measures (approximately 65-90 minutes) 
i. Beck Depression Inventory, Second Edition (BDI-II) 
ii. Penn State Worry Questionnaire (PSWQ) 
iii. PTSD Checklist (PTSD-C) 
iv. Emotion Regulation Questionnaire (ERQ) 
v. Dissociative Experiences Scale, Second Edition (DES-II) 
vi. Trauma Symptom Inventory (TSI) 
vii. Minnesota Multiphasic Personality Inventory, Second Edition, 
Restructured Format (MMPI-2-RF) 
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Appendix B: Tables and Figures 
Table 1. Demographic profiles of motor symptom subgroups. 
 
Variable PNES PMD t/χ2 p 
Age (years) 
     At Time of Testing 
     At Symptom Onset 
 
39.8 (10.3) 
36.2 (10.2) 
 
44.6 (14.0) 
41.3 (12.1) 
 
— 
— 
 
ns 
ns 
Educationa 12.9 (2.36) 14.3 (2.08) 73.0 0.03 
Gender (% female) 15 (93.8%) 15 (93.8%) — ns 
Handedness (% right) 13 (81.3%) 11 (68.8%) — ns 
Ethnicity 
     Caucasian 
     Hispanic 
     African American 
 
11 (68.8%) 
3 (18.8%) 
2 (12.5%) 
 
10 (62.5%) 
3 (18.8%) 
3 (18.8%) 
 
— 
 
ns 
Marital Status 
     Married 
     Single 
     Widowed 
     Divorced 
 
6 (37.5%) 
6 (37.5%) 
2 (12.5%) 
2 (12.5%) 
 
13 (81.3%) 
1 (6.30%) 
- 
2 (12.5%) 
 
8.15 
 
0.04 
Functional Status 
     Employed 
     Disability/Unemployed 
 
2 (12.5%) 
14 (87.5%) 
 
9 (56.3%) 
7 (43.8%) 
 
6.79 
 
0.009 
Medical History 
     Fibromyalgia 
     Migraine headaches 
     Head injury w/o LOC 
 
3 (18.8%) 
13 (81.3%) 
5 (31.3%) 
 
1 (6.30%) 
11 (68.8%) 
4 (25.0%) 
 
— 
 
ns 
Psychiatric History 
     Mood disorder 
     Anxiety-related disorder 
     Somatoform disorder 
     Dissociative disorder 
     Personality disorder 
 
6 (37.5%) 
7 (43.8%) 
2 (12.5%) 
- 
1 (6.30%) 
 
6 (37.5%) 
6 (37.5%) 
2 (12.5%) 
2 (12.5%) 
- 
 
— 
 
ns 
Current Treatment 
     Antidepressant 
     Benzodiazepine 
     Anticonvulsant 
     Opiate agonist 
     Counseling 
 
5 (31.3%) 
8 (50.0%) 
10 (62.5%) 
7 (43.8%) 
5 (31.3%) 
 
10 (62.5%) 
7 (43.8%) 
10 (62.5%) 
9 (56.3%) 
5 (31.3%) 
 
— 
 
ns 
Note. Mean (SD) and frequency (%) are provided for each variable. 
ns = not statistically significant at p < 0.05 
aMann-Whitney U test was performed for this variable. 
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Table 2. Trauma history and posttraumatic symptomatology across groups. 
 
Variable PNES PMD t/χ2 p 
DES-II Total 20.3 (16.3) 20.9 (18.1) — ns 
PTSD Checklist Total 43.7 (14.8) 42.4 (16.9) — ns 
Trauma History 
     Sexual abuse 
     Physical abuse 
     Emotional/Verbal abuse 
     Neglect/Abandonment 
     Natural disaster 
     Family Conflict 
 
6 (37.5%) 
2 (12.5%) 
- 
5 (31.3%) 
4 (25.0%) 
2 (12.5%) 
 
1 (6.30%) 
5 (31.3%) 
3 (18.8%) 
4 (25.0%) 
5 (31.3%) 
3 (18.8%) 
 
4.57 
— 
— 
— 
— 
— 
 
0.03 
ns 
ns 
ns 
ns 
ns 
Note. Mean (SD) and frequency (%) are provided for each variable. 
ns = not statistically significant at p < 0.05 
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Appendix B (Continued) 
Table 3. Affective symptomatology across groups. 
 
Variable PNES PMD t p 
BDI-II 22.8 (14.4) 16.3 (10.2) — ns 
PSWQ 51.3 (15.1) 48.8 (15.8) — ns 
ERQ 
     Suppression 
     Reappraisal 
 
4.02 (1.64) 
4.81 (1.01) 
 
3.35 (1.37) 
4.69 (1.21) 
 
— 
— 
 
ns 
ns 
Note. Mean (SD) are provided for each variable. 
ns = not statistically significant at p < 0.05 
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Table 4. Neuropsychological performance across groups. 
 
Variable PNES PMD t p 
WTARa 95.4 (12.7) 101.5 (14.5) — ns 
MoCA Total Score 
     Visuospatial/Executive 
     Naming 
     Attention 
     Language 
     Abstraction 
     Memory 
     Orientation 
23.1 (4.27) 
4.69 (1.25) 
3.00 (0.00) 
3.94 (1.57) 
1.94 (1.18) 
1.00 (0.82) 
3.56 (1.55) 
5.88 (0.34) 
25.0 (3.46) 
5.19 (1.68) 
3.00 (0.00) 
5.25 (0.93) 
2.37 (0.72) 
1.19 (0.75) 
3.31 (1.99) 
5.94 (0.25) 
— 
— 
— 
-2.88 
— 
— 
— 
— 
ns 
ns 
ns 
0.007 
ns 
ns 
ns 
ns 
Digit Span (WAIS-IV)b 41.8 (11.7) 45.1 (6.46) — ns 
TMT 
     Trails A 
     Trails B 
 
40.9 (15.6) 
38.6 (17.0) 
 
38.2 (13.4) 
35.8 (13.4) 
 
— 
— 
 
ns 
ns 
Verbal Fluency 
     Lexical (FAS) 
     Semantic (Animals) 
 
33.1 (9.26) 
38.2 (8.87) 
 
43.7 (9.54) 
42.3 (11.4) 
 
-3.44 
— 
 
0.002 
ns 
WCST-64 
     Total Errors 
     Perseverative Errors 
     Perseverative Responses 
 
42.5 (11.3) 
41.3 (10.3) 
55.5 (10.5) 
 
44.4 (9.05) 
42.6 (7.98) 
72.8 (14.4) 
 
— 
— 
-3.87 
 
ns 
ns 
0.001 
Note. Mean (SD) t-scores are provided for each variable, with the exception of the 
WTAR (standard scores) and the MoCA (raw scores).  
ns = not statistically significant at p < 0.05 
aANCOVA with education as a covariate was performed for this variable. 
bMann-Whitney U test was performed for this variable. 
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Figure 1. Mean t-scores for PNES and other PMD groups on MMPI-2-RF RC scales.  Error bars 
represent standard errors.  Scale abbreviations are as follows: RCd = Demoralization; RC1 = Somatic 
Complaints; RC2 = Low Positive Emotions; RC3 = Cynicism; RC4 = Antisocial Behavior; RC6 = 
Ideas of Persecution; RC7 = Dysfunctional Negative Emotions; RC8 = Aberrant Experiences; RC9 = 
Hypomanic Activation.
Figure 1.  Comparison of MMPI-2-RF Restructured Clinical (RC) scales
between groups.
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Figure 2. MoCA performance by domain for combined 
groups in relation to normative data.
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Figure 3. Neuropsychological profile of combined groups 
in relation to normative data.
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